Assembling OX40 Aptamers on a Molecular Scaffold to Create a Receptor-Activating Aptamer

Chemistry and Biology

Volumn 15, Issue 7, 2008, Pages 675-682

  Dollins, Claudia M ^a,b   Nair, Smita ^b   Boczkowski, David ^b   Lee, Jaewoo ^b   Layzer, Juliana M ^b   Gilboa, Eli ^c   Sullenger, Bruce A ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

CHEMBIO; RNA

Indexed keywords

CANCER VACCINE; CD134 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGAND; PEPTIDE APTAMER;

ANIMAL; ARTICLE; C57BL MOUSE; CANCER TRANSPLANTATION; CHEMISTRY; CYTOLOGY; DENDRITIC CELL; DRUG DESIGN; FEMALE; METABOLISM; METHODOLOGY; MOUSE; PHARMACEUTICS;

ANIMALS; APTAMERS, PEPTIDE; CANCER VACCINES; CHEMISTRY, PHARMACEUTICAL; DENDRITIC CELLS; DRUG DESIGN; FEMALE; LIGANDS; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NF-KAPPA B; RECEPTORS, OX40; TECHNOLOGY, PHARMACEUTICAL;

MUS;

EID: 46849111987     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2008.05.016     Document Type: Article

References (32)

1. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3 (2003) 745-756
2. Ali S.A., Ahmad M., Lynam J., McLean C.S., Entwisle C., Loudon P., Choolun E., McArdle S.E., Li G., Mian S., et al. Anti-tumour therapeutic efficacy of OX40L in murine tumour model. Vaccine 22 (2004) 3585-3594
3. al-Shamkhani A., Birkeland M.L., Puklavec M., Brown M.H., James W., and Barclay A.N. OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand. Eur. J. Immunol. 26 (1996) 1695-1699
4. Arch R.H., and Thompson C.B. 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB. Mol. Cell. Biol. 18 (1998) 558-565
5. Burmeister P.E., Lewis S.D., Silva R.F., Preiss J.R., Horwitz L.R., Pendergrast P.S., McCauley T.G., Kurz J.C., Epstein D.M., Wilson C., et al. Direct in vitro selection of a 2′-O-methyl aptamer to VEGF. Chem. Biol. 12 (2005) 25-33
6. Compaan D.M., and Hymowitz S.G. The crystal structure of the costimulatory OX40-OX40L complex. Structure 14 (2006) 1321-1330
7. Dyke C.K., Steinhubl S.R., Kleiman N.S., Cannon R.O., Aberle L.G., Lin M., Myles S.K., Melloni C., Harrington R.A., Alexander J.H., et al. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 114 (2006) 2490-2497
8. Ellington A.D., and Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 346 (1990) 818-822
9. Fitzwater T., and Polisky B. A SELEX primer. Methods Enzymol. 267 (1996) 275-301
10. Fournel S., Wieckowski S., Sun W., Trouche N., Dumortier H., Bianco A., Chaloin O., Habib M., Peter J.C., Schneider P., et al. C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L. Nat. Chem. Biol. 1 (2005) 377-382
11. Kawamata S., Hori T., Imura A., Takaori-Kondo A., and Uchiyama T. Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-κB activation. J. Biol. Chem. 273 (1998) 5808-5814
12. Kleinman M.E., Yamada K., Takeda A., Chandrasekaran V., Nozaki M., Baffi J.Z., Albuquerque R.J., Yamasaki S., Itaya M., Pan Y., et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452 (2008) 591-597
13. Layzer J.M., and Sullenger B.A. Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection. Oligonucleotides 17 (2007) 1-11
14. Macugen AMD Study Group, Apte R.S., Modi M., Masonson H., Patel M., Whitfield L., and Adamis A.P. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology 114 (2007) 1702-1712
15. McNamara J.O., Kolonias D., Pastor F., Mittler R.S., Chen L., Giangrande P.H., Sullenger B., and Gilboa E. Multivalent 4-1BB binding aptamers costimulate CD8 T cells and inhibit tumor growth in mice. J. Clin. Invest. 118 (2007) 376-386
16. Melero I., Hervas-Stubbs S., Glennie M., Pardoll D.M., and Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 7 (2007) 95-106
17. Mi J., Zhang X., Rabbani Z.N., Liu Y., Su Z., Vujaskovic Z., Kontos C.D., Sullenger B.A., and Clary B.M. H1 RNA polymerase III promoter-driven expression of an RNA aptamer leads to high-level inhibition of intracellular protein activity. Nucleic Acids Res. 34 (2006) 3577-3584
18. Morris N.P., Peters C., Montler R., Hu H.M., Curti B.D., Urba W.J., and Weinberg A.D. Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain. Mol. Immunol. 44 (2007) 3112-3121
19. Nair S., and Boczkowski D. RNA-transfected dendritic cells. Expert Rev. Vaccines 1 (2002) 507-513
20. Nair S., Boczkowski D., Fassnacht M., Pisetsky D., and Gilboa E. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res. 67 (2007) 371-380
21. Nimjee S.M., Rusconi C.P., and Sullenger B.A. Aptamers: an emerging class of therapeutics. Annu. Rev. Med. 56 (2005) 555-583
22. Nimjee S.M., Keys J.R., Pitoc G.A., Quick G., Rusconi C.P., and Sullenger B.A. A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Mol. Ther. 14 (2006) 408-415
23. Porgador A., Gansbacher B., Bannerji R., Tzehoval E., Gilboa E., Feldman M., and Eisenbach L. Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells. Int. J. Cancer 53 (1993) 471-477
24. Rusconi C.P., Scardino E., Layzer J., Pitoc G.A., Ortel T.L., Monroe D., and Sullenger B.A. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419 (2002) 90-94
25. Santulli-Marotto S., Nair S.K., Rusconi C., Sullenger B., and Gilboa E. Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res. 63 (2003) 7483-7489
26. Sugamura K., Ishii N., and Weinberg A.D. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat. Rev. Immunol. 4 (2004) 420-431
27. Talmage D.W., Woolnough J.A., Hemmingsen H., Lopez L., and Lafferty K.J. Activation of cytotoxic T cells by nonstimulating tumor cells and spleen cell factor(s). Proc. Natl. Acad. Sci. USA 74 (1977) 4610-4614
28. Tuerk C., and Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249 (1990) 505-510
29. Watts T.H. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23 (2005) 23-68
30. Weinberg A.D. OX40: targeted immunotherapy-implications for tempering autoimmunity and enhancing vaccines. Trends Immunol. 23 (2002) 102-109
31. Weinberg A.D., Thalhofer C., Morris N., Walker J.M., Seiss D., Wong S., Axthelm M.K., Picker L.J., and Urba W.J. Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study. J. Immunother. 29 (2006) 575-585
32. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31 (2003) 3406-3415